Charles Schwab Investment Management Inc Eye Point Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 142,763 shares of EYPT stock, worth $1.71 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
142,763
Previous 134,796
5.91%
Holding current value
$1.71 Million
Previous $1.17 Million
2.73%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding EYPT
# of Institutions
156Shares Held
57.5MCall Options Held
224KPut Options Held
1.41M-
Cormorant Asset Management, LP Boston, MA8.33MShares$99.9 Million5.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$62.1 Million1.88% of portfolio
-
Franklin Resources Inc San Mateo, CA4.01MShares$48.1 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$45.2 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.59MShares$43.1 Million0.06% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $409M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...